Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, swinging +197.96% from a $59.29 low to a $176.66 high before settling at $154.27 — a period return of +154.69% and a close at 80.93% of its range. Its 405.33% realized volatility against 79.74% implied produced a 16.77x realized/implied ratio, the largest mispricing in the group by a wide margin. Other biotech and health-tech names followed the same pattern of options underpricing the move: BNTX (4.02x), HIMS (4.06x), TEM (6.13x), and even large-cap MRK (4.06x, IV just 27.34%).

The reverse held in the low-priced, high-IV names. CDXS (366.41% IV, 0.27x), KPTI (421.09% IV, 0.17x), DBVT (0.58x), and STIM (0.68x) all carried extreme implied vol against far tamer realized moves.

Range positioning split sharply. CVS closed at 100.00% of its range and GILD at 99.64%, with EBS at 96.59% — persistent strength into the close. At the other end, SYK finished at 1.96%, ADUS at 6.65%, CDXS at 7.86%, LLY at 8.93%, and ANAB at 8.96%, all fading toward their lows.

Broader Market Context

Differential behavior within the sector. The dispersion here is unusually wide for a single sector: roughly 218 percentage points separate MRNA (+197.96%) from STIM (-20.06%). That spread is far too large to be explained by a common sector factor. Three sub-groups pulled apart clearly:

• Large-cap pharma and managed care clustered tightly in the +5% to +22% band — MRK, GILD, AMGN, BMY, ABBV, JNJ, CI, ELV, HUM — with modest implied vols (22–38%) and realized vols mostly in the 19–31% range. XLV's +6.54% sits in the middle of this cohort, consistent with the sector ETF being dragged by these weights.
• Biotech and health-tech (MRNA, TEM, BNTX, HIMS, QURE, EBS) delivered the outsized moves and nearly all of the realized-over-implied surprises.
• Laggards skewed toward devices and small-cap therapeutics — SYK (-8.81%), ADMA, ANAB, MGNX, DBVT, KPTI, STIM — plus LLY (-11.27%), a notable divergence from its large-cap peers.

Rotation vs. idiosyncratic moves. The evidence leans idiosyncratic rather than rotational. A clean defensive rotation *into* healthcare would lift the group broadly with compressed dispersion; instead, insurers and pharma rose while devices and small-cap biotech fell. LLY moving sharply lower while MRK and ABBV rallied is particularly hard to reconcile with a sector-wide flow story. That said, the steady bid under CVS, GILD, and the managed-care names — closing at 75–100% of their ranges — is *consistent with* some defensive positioning into large-cap healthcare, likely reflecting broader risk appetite shifting rather than sector-specific enthusiasm.

Plausible current-event backdrop. Without asserting specific headlines, the volatility signature fits several familiar sector drivers:

• Clinical or regulatory catalysts in biotech, which typically produce exactly the gap-and-hold pattern MRNA, TEM, and BNTX show — and exactly the kind of realized-over-implied surprise (4x–17x) that options markets struggle to price.
• Ongoing drug-pricing, reimbursement, and policy uncertainty, which tends to compress and separate managed care from pharma, potentially relevant to the UNH/CNC weakness against HUM/ELV/CI strength.
• Persistently elevated implied vol in microcaps (CDXS, KPTI above 360%) that failed to realize, consistent with event risk being priced but not resolved within the window.